A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer
10.1016/j.annonc.2023.05.002 · doi-reference
Immunomodulatory effects of lenvatinib in patients with advanced thyroid cancer
10.1007/s00262-025-04241-7 · doi-reference
Preclinical evaluation of novel tyrosine-kinase inhibitors in medullary thyroid cancer
10.3390/cancers14184442 · doi-reference
Metabolic reprogramming and immunosenescence in colorectal cancer: mechanisms and therapeutic implications
10.3389/fcell.2025.1662464 · doi-reference
Neutrophil diversity is associated with T-cell immunity and clinical relevance in patients with thyroid cancer
10.1038/s41420-024-01970-z · doi-reference
Metformin reprograms tryptophan metabolism to stimulate CD8+ T-cell function in colorectal cancer
10.1158/0008-5472.can-22-3042 · doi-reference
Integration of metabolomics and transcriptomics reveals metformin suppresses thyroid cancer progression via inhibiting glycolysis and restraining DNA replication
10.1016/j.biopha.2023.115659 · doi-reference
Case report: a multi-peptide vaccine targeting individual somatic mutations induces tumor infiltration of neoantigen-specific T cells in a patient with metastatic colorectal cancer
10.3390/vaccines13090960 · doi-reference
Tubeimuside I improves the efficacy of a therapeutic Fusobacterium nucleatum dendritic cell-based vaccine against colorectal cancer
10.3389/fimmu.2023.1154818 · doi-reference
Dendritic cell vaccine therapy for colorectal cancer
10.1016/j.phrs.2020.105374 · doi-reference
Dendritic cell vaccination in medullary thyroid carcinoma
10.1158/1078-0432.ccr-03-0698 · doi-reference
Immunotherapy in initial treatment of anaplastic thyroid cancer: evaluation of overall survival in a national cancer database study
10.1177/10507256251372191 · doi-reference
Tumor-infiltrating immune cell landscapes in the lymph node metastasis of papillary thyroid cancer
10.3390/curroncol30030200 · doi-reference
Dynamics of the Γδtcr repertoires during the dedifferentiation process and pilot implications for immunotherapy of thyroid cancer
10.1002/advs.202306364 · doi-reference
Tumor-infiltrating T lymphocytes recognize thyroid-specific proteins and neo-antigens in follicular cell-derived thyroid cancers
10.1210/clinem/dgaf639 · doi-reference
DNTGF-βR armored CAR-T cell therapy against tumors from bench to bedside
10.1186/s12967-023-04829-6 · doi-reference
Enhanced efficacy of dual chimeric antigen receptor-T cells targeting programmed death-ligand 1 and cancer-associated fibroblasts in colorectal cancer in vitro
10.25259/cytojournal_245_2024 · doi-reference
Hypoxia promotes Malignant progression of colorectal cancer by inducing POSTN(+) cancer-associated fibroblast formation
10.1002/mc.23882 · doi-reference
Lipopolysaccharide induces resistance to CAR-T cell therapy of colorectal cancer cells through TGF-β-mediated stemness enhancement
10.1021/acs.molpharmaceut.4c00264 · doi-reference
CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer
10.1016/j.phrs.2024.107126 · doi-reference
Targeting CSF1R in myeloid-derived suppressor cells: insights into its immunomodulatory functions in colorectal cancer and therapeutic implications
10.1186/s12951-024-02584-4 · doi-reference
Efficacy and safety of fruquintinib combined with immunotherapy in later-line treatment of metastatic colorectal cancer
10.3892/ol.2025.15287 · doi-reference
Vascular normalization was associated with colorectal tumor regression upon anti-PD-L1 combinational therapy
10.1155/2023/5867047 · doi-reference
The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer
10.1038/s41590-024-02068-5 · doi-reference
USP15 facilitates colorectal cancer immune evasion through SMYD3/CCL2-dependent myeloid-derived suppressor cell recruitment
10.1158/2326-6066.cir-24-1194 · doi-reference
Tumor-associated macrophages as a potential therapeutic target in thyroid cancers
10.1007/s00262-023-03549-6 · doi-reference
IL2RA(+)VSIG4(+) tumor-associated macrophage is a key subpopulation of the immunosuppressive microenvironment in anaplastic thyroid cancer
10.1016/j.bbadis.2022.166591 · doi-reference
Sirpα on tumor-associated myeloid cells restrains antitumor immunity in colorectal cancer independent of its interaction with CD47
10.1038/s43018-023-00691-z · doi-reference
HN1/CEBPB/CCL2 signaling shapes VSIG4(+) tumor-associated macrophages in anaplastic thyroid carcinoma
10.1016/j.bbadis.2026.168303 · doi-reference
Myeloid-derived suppressor cells in anaplastic thyroid carcinoma: insights from prospective immune profiling and implications for targeted immunotherapy
10.1136/jcp-2025-210585 · doi-reference
Nivolumab plus ipilimumab in microsatellite-instability-high metastatic colorectal cancer
10.1056/nejmoa2402141 · doi-reference
Genomic landscape and clinical features of advanced thyroid carcinoma: a national database study in Japan
10.1210/clinem/dgae271 · doi-reference
The genomic and evolutionary landscapes of anaplastic thyroid carcinoma
10.1016/j.celrep.2024.113826 · doi-reference
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study
10.1002/cncr.34657 · doi-reference
Validation of the prognostic value of CD3 and CD8 cell densities analogous to the Immunoscore® by stage and location of colorectal cancer: an independent patient cohort study
10.1002/cjp2.304 · doi-reference
A tumor-intrinsic WNT-inhibitory NOTUM program drives immune resistance in microsatellite stable colorectal cancer
10.1016/j.xcrm.2026.102776 · doi-reference
Neurotrophic tyrosine receptor kinase gene fusions in adult and pediatric patients with solid tumors: a clinicogenomic biobank and record linkage study of expression frequency and patient characteristics from Finland
10.2340/1651-226x.2024.26452 · doi-reference
Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes
10.1016/j.esmoop.2024.104108 · doi-reference
A Tc1- and Th1-T-lymphocyte-rich tumor microenvironment is a hallmark of MSI colorectal cancer
10.1002/path.6415 · doi-reference
Indoleamine 2,3-dioxygenase immune status as a potential biomarker of radioiodine efficacy for advanced distant metastatic differentiated thyroid cancer
10.3389/fonc.2022.871792 · doi-reference
